

Florian Krismer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4546887/publications.pdf>

Version: 2024-02-01

89
papers

4,687
citations

196777

29
h-index

120465

65
g-index

95
all docs

95
docs citations

95
times ranked

5041
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple System Atrophy (MSA). , 2022, , 2409-2432.		0
2	Cardiac sympathetic innervation in Parkinsonâ€™s disease versus multiple system atrophy. Clinical Autonomic Research, 2022, 32, 103-114.	1.4	7
3	Differentiating Parkinsonâ€™s Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1115-1123.	1.5	7
4	Sensitivity to Change and Patientâ€™Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Dataâ€™Driven Analysis. Movement Disorders, 2022, 37, 1425-1431.	2.2	8
5	Development and Validation of Automated <sc>Magnetic Resonance</sc> Parkinsonism Index 2.0 to Distinguish <sc>Progressive Supranuclear Palsyâ€™Parkinsonism</sc> From <sc>Parkinson's Disease</sc>. Movement Disorders, 2022, 37, 1272-1281.	2.2	17
6	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2022, 37, 1131-1148.	2.2	222
7	Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?. Journal of Parkinson's Disease, 2022, 12, 1369-1387.	1.5	10
8	Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Postâ€™hoc Analysis of <sc>NMSâ€™Nab</sc> Study. Movement Disorders Clinical Practice, 2022, 9, 751-758.	0.8	10
9	Eye Tracking in Patients with Parkinsonâ€™s Disease Treated with Nabiloneâ€™Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study. Brain Sciences, 2022, 12, 661.	1.1	4
10	Disease Progression in Multiple System Atrophyâ€™Novel Modeling Framework and Predictive Factors. Movement Disorders, 2022, 37, 1719-1727.	2.2	7
11	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. Movement Disorders, 2021, 36, 681-689.	2.2	22
12	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. Parkinsonism and Related Disorders, 2021, 82, 87-91.	1.1	16
13	Automated Analysis of Diffusionâ€™Weighted <sc>Magnetic Resonance Imaging</sc> for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. Movement Disorders, 2021, 36, 241-245.	2.2	15
14	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. Clinical Autonomic Research, 2021, 31, 157-164.	1.4	22
15	Laboratoryâ€™Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the <sc>MoDiMSA Study Group</sc>. Movement Disorders Clinical Practice, 2021, 8, 322-340.	0.8	7
16	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. Parkinsonism and Related Disorders, 2021, 85, 30-36.	1.1	8
17	Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis. Journal of Neural Transmission, 2021, 128, 1497-1505.	1.4	7
18	The Parkinson disease connectome â€™ insights from new imaging studies. Nature Reviews Neurology, 2021, 17, 527-528.	4.9	5

#	ARTICLE	IF	CITATIONS
19	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1052-1060.	0.8	6
20	Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1833-1843.	1.5	3
21	Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. <i>Annals of Neurology</i> , 2020, 88, 712-722.	2.8	55
22	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
23	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020, 35, 976-983.	2.2	38
24	Diagnostic potential of automated tractography in progressive supranuclear palsy variants. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 65-71.	1.1	11
25	Cognition in multiple system atrophy: a single-center cohort study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 219-228.	1.7	31
26	No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements. <i>European Radiology</i> , 2020, 30, 2802-2808.	2.3	5
27	Extending the spectrum of non-motor symptoms with olfaction in pre-motor Huntington's disease – a pilot study. <i>Neurodegenerative Diseases</i> , 2020, 20, 207-211.	0.8	1
28	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 23-27.	1.1	16
29	Comment: Autologous mesenchymal stem cells. <i>Neurology</i> , 2019, 93, 25-25.	1.5	0
30	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 60-65.	1.1	23
31	Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. <i>The Lancet Digital Health</i> , 2019, 1, e222-e231.	5.9	73
32	L-dopa response pattern in a rat model of mild striatonigral degeneration. <i>PLoS ONE</i> , 2019, 14, e0218130.	1.1	0
33	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	2.2	73
34	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. <i>Movement Disorders</i> , 2019, 34, 1041-1048.	2.2	36
35	Imaging markers of disease progression in multiple system atrophy. <i>Future Neurology</i> , 2019, 14, FNL24.	0.9	3
36	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019, 149, 137-192.	0.9	74

#	ARTICLE	IF	CITATIONS
37	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. <i>Gerontology</i> , 2019, 65, 216-228.	1.4	63
38	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 90-94.	1.1	49
39	Key themes and future prospects in translational multiple system atrophy research. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 211, 43-45.	1.4	0
40	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.5	23
41	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 47-55.	1.1	45
42	Structural Imaging in Atypical Parkinsonism. <i>International Review of Neurobiology</i> , 2018, 142, 67-148.	0.9	27
43	Diagnosis of PSP-P: Can a newly developed MRPI make the difference?. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 1-2.	1.1	1
44	Sensor-based gait analysis in atypical parkinsonian disorders. <i>Brain and Behavior</i> , 2018, 8, e00977.	1.0	43
45	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	1.1	17
46	Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 619-623.	2.2	129
47	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
48	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
49	Magnetic resonance imaging for the diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 915-964.	1.4	178
50	Multiple system atrophy: insights into a rare and debilitating movement disorder. <i>Nature Reviews Neurology</i> , 2017, 13, 232-243.	4.9	128
51	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. <i>Movement Disorders</i> , 2017, 32, 1457-1464.	2.2	60
52	Putaminal diffusion imaging for the differential diagnosis of the parkinsonian variant of multiple system atrophy from Parkinson's disease: Impact of segmentation accuracy. <i>Journal of the Neurological Sciences</i> , 2017, 381, 223.	0.3	0
53	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017, 124, 293-302.	1.4	46
54	Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 36-41.	1.1	67

#	ARTICLE	IF	CITATIONS
55	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0189897.	1.1	44
56	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. Movement Disorders, 2016, 31, 235-240.	2.2	9
57	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. Movement Disorders, 2016, 31, 1577-1581.	2.2	14
58	Anatomical profile of cognitive impairment in MSA. Parkinsonism and Related Disorders, 2016, 22, e118.	1.1	0
59	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. Movement Disorders, 2016, 31, 1408-1413.	2.2	55
60	1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism. Movement Disorders, 2016, 31, 1925-1927.	2.2	8
61	Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. Neurotherapeutics, 2016, 13, 871-879.	2.1	17
62	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	1.4	32
63	New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 554-561.	0.9	48
64	Interventional trials in atypical parkinsonism. Parkinsonism and Related Disorders, 2016, 22, S82-S92.	1.1	19
65	Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Movement Disorders, 2015, 30, 1068-1076.	2.2	125
66	Therapeutic advances in multiple system atrophy and progressive supranuclear palsy. Movement Disorders, 2015, 30, 1528-1538.	2.2	17
67	Multiple system atrophy in the USA: another piece in the jigsaw. Lancet Neurology, The, 2015, 14, 672-674.	4.9	0
68	Multiple system atrophy—new insight from prospective studies. Nature Reviews Neurology, 2015, 11, 430-431.	4.9	2
69	Multiple system atrophy: the case for an international collaborative effort. Clinical Autonomic Research, 2015, 25, 81-83.	1.4	8
70	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiology of Disease, 2015, 80, 29-41.	2.1	71
71	Sex and age effects on cardiovascular autonomic function in healthy adults. Clinical Autonomic Research, 2015, 25, 317-326.	1.4	24
72	Animal Models of Multiple-System Atrophy. , 2015, , 887-904.		0

#	ARTICLE	IF	CITATIONS
73	An update on the cerebellar subtype of multiple system atrophy. <i>Cerebellum and Ataxias</i> , 2014, 1, 14.	1.9	16
74	Rifampicin for multiple system atrophy. <i>Lancet Neurology</i> , The, 2014, 13, 237-239.	4.9	3
75	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.	2.2	193
76	Autonomic failure in CANVAS syndrome. <i>Brain</i> , 2014, 137, 2625-2626.	3.7	4
77	Multiple system atrophy as emerging template for accelerated drug discovery in $\hat{\pm}$ -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 793-799.	1.1	18
78	Aetiopathogenesis. , 2014, , 57-81.		3
79	Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. <i>Journal of Neurology</i> , 2013, 260, 2212-2219.	1.8	106
80	Multiple system atrophy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 117, 229-241.	1.0	31
81	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 264-274.	4.9	426
82	Multiple System Atrophy (MSA). , 2013, , 2119-2141.		0
83	Intact Olfaction in a Mouse Model of Multiple System Atrophy. <i>PLoS ONE</i> , 2013, 8, e64625.	1.1	20
84	Multiple System Atrophy (MSA). , 2013, , 129-138.		1
85	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. <i>Movement Disorders</i> , 2012, 27, 1683-1685.	2.2	18
86	Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study. <i>Cerebellum</i> , 2012, 11, 223-226.	1.4	22
87	New insights into atypical parkinsonism. <i>Current Opinion in Neurology</i> , 2011, 24, 331-338.	1.8	27
88	Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. <i>Movement Disorders</i> , 2011, 26, 507-515.	2.2	17
89	Saccadic latency in hepatic encephalopathy: a pilot study. <i>Metabolic Brain Disease</i> , 2010, 25, 285-295.	1.4	9